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The ID1 protein, an inhibitor of basic helix–loop–helix transcription factors, has been involved in multiple cellular processes including
cell cycle regulation, apoptosis, and angiogenesis. To evaluate the importance of ID1 in malignant melanoma, tumour cell expression
was examined by immunohistochemistry in 119 cases of nodular melanoma using tissue microarray technique, and related to multiple
tumour markers including proliferation, p16 expression, angiogenesis and patient survival. Strong ID1 expression was significantly
associated with increased tumour thickness, and significantly reduced survival. Also, increased ID1 was associated with loss of
thrombospondin-1 (TSP-1) expression, a known inhibitor of angiogenesis, and increased intensity of ephrin-A1 and its receptor
EPHA2. Presence of BRAF mutations was related to strong ID1 expression, but there was no relationship with p16 protein
expression. Further, no significant correlation was found between ID1 and microvessel density. In conclusion, our study supports a
significant role of the ID1 protein in melanoma progression and patient prognosis. The absence of correlation with p16 protein
expression and angiogenesis suggests that other regulatory pathways and mechanisms might be influenced by ID1 in melanomas. An
inverse relation between ID1 and TSP-1 expression support an important role of ID1 in the regulation of this complex multitarget
protein.
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Several molecular pathways are important for the development and
progression of cutaneous melanoma (Herlyn et al, 2000; Bennett
and Medrano, 2002) (Keller-Melchior-98, Pavey-02), and we have
previously reported that both tumour cell proliferation and
angiogenesis are increased in aggressive tumour subgroups
(Straume et al, 2000; Straume and Akslen, 2001). Especially,
deregulation of the CDKN2A/p16 pathway was apparent with loss
of p16 protein expression in 45% of the cases (Straume et al, 2000;
Straume and Akslen, 2001), although the mechanisms are not
clear. Lack of p16 expression was associated with increased
tumour cell proliferation by Ki-67 expression and reduced survival
in melanomas. In addition, we found a strong prognostic impact of
angiogenesis as estimated by microvessel density (MVD), as well as
significant influence of thrombospondin-1 (TSP-1) staining in the
tumour stroma (Straume and Akslen, 2001). The purpose of
our present study was to examine the possible regulatory role of
ID1 and ETS transcription factors in melanoma progression,
especially since they are known to influence both the CDKN2A/p16
pathway and angiogenesis regulation (Yates et al, 1999; Alani et al,
2001).
The family of Id proteins consists of four members capable of
inhibiting basic helix–loop–helix transcription factors (Norton
et al, 1998). Recent studies have implicated a regulatory role of Id
proteins in multiple processes such as cell cycle progression
(Lasorella et al, 1996; Israel et al, 1999), apoptosis (Norton and
Atherton, 1998), and angiogenesis (Lyden et al, 1999; Schoppmann
et al, 2003). Regarding tumour cell proliferation, Alani et al (2001)
showed an inhibitory interaction between ID1 protein and the
promoter region of the tumour suppressor gene CDKN2A/p16,
supporting a role of ID1 as a potential oncogene. It was further
shown that Id proteins also inhibit ETS transcription factors (Yates
et al, 1999) which are able to influence p16 expression by binding
to and activate its promoter (Ohtani et al, 2001). This indicates
that Id proteins might inhibit the p16 promoter, and thereby
increase tumour cell proliferation, both directly and indirectly via
interactions with ETS transcription factors.
Both Id proteins and ETS transcription factors have previously
been implicated in the regulation of angiogenesis (Lyden et al,
1999; Wernert et al, 2003). Id proteins were shown to influence
VEGF-dependent mobilisation of circulating endothelial cells
and endothelial precursor cells from the bone marrow (Lyden
et al, 2001). Further, ID1 might act by transcriptional repression
of TSP-1, a well-known angiogenesis inhibitor (Volpert et al,
2002).
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sRegarding malignant melanoma, ID1 mRNA expression,
assessed by in situ hybridisation, has been associated with loss
of p16 protein in melanoma in situ (Polsky et al, 2001). In invasive
melanomas, ID1 mRNA positivity was limited to the in situ
component and perivascular tumour areas. These data might
suggest a role of ID1 in regulating p16 expression in some early
melanomas (Polsky et al, 2001). In our present study of nodular
melanomas, which are considered to be more advanced primary
tumours, we found no association between ID1 or ETS-1
transcription factor and p16 expression or angiogenic markers.
On the other hand, strong ID1 expression was associated with
thicker primary tumours and presence of BRAF mutations, as well
as with significantly reduced patient survival, indicating an
important role in melanoma progression. An inverse relation
between ID1 and TSP-1 expression support a significant role of
ID1 in the regulation of this complex and multitarget protein.
MATERIALS AND METHODS
Of all melanomas occurring in Hordaland County (10% of the
Norwegian population) during 1981–1997, 97.5% were diagnosed
at The Gade Institute, Section for Pathology, Haukeland University
Hospital. There were no differences in sex, anatomic site or stage
between these cases and the 2.5% with a diagnosis from other
laboratories, although the latter patients were 6 years younger
(median age). The aim of this study was to focus on the aggressive
subgroup consisting of nodular melanomas, which are all vertical
growth phase (VGP) melanomas. After microscopic review of all
cases diagnosed and recorded as malignant melanoma of the
nodular type or not otherwise specified during this period, 202
cases were included. The presence of a VGP and the lack of a radial
growth phase, that is, adjacent in situ or microinvasive component,
were used as inclusion criteria (Elder and Murphy, 1991), and only
primary tumours were included after careful examination of all
slides. There was no history of familial occurrence. Complete
information on patient survival, time and cause of death was
available in all 202 cases. Last date of follow-up was December 18,
1998, and median follow-up time for all survivors was 76 months
(range 13–210). Clinical follow-up (with respect to recurrences)
was not carried out in 14 (mostly older) patients, and 21 patients
were not treated with complete local excision. Thus, recurrence-
free time could be studied in 167 patients.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on formalin-fixed
and paraffin-embedded archival tissue. The technique of tissue
microarray (TMA) was recently introduced (Kononen et al, 1998)
and validated by independent studies of several tumour markers
(Hoos et al, 2001; Nocito et al, 2001), and TMA slides were used for
the staining of ID1 and ETS-1. For TMA construction (Kononen
et al, 1998; Nocito et al, 2001), representative tumour areas were
identified on H&E-stained slides. Tissue cylinders with a diameter
of 0.6mm were then punched from selected areas of the ‘donor’
block and mounted into a ‘recipient’ paraffin block using a
custom-made precision instrument (Beecher Instruments, Silver
Springs, MD, USA). As recommended (Hoos et al, 2001), three
parallel tissue cylinders were sampled from each case, and these
were taken from the suprabasal areas of the primary tumours. In
some cases, a sufficient amount of tumour tissue was not available
in the remaining paraffin blocks and 147 primary tumours and 56
metastases were available using the TMA technique. There was no
significant difference regarding MVD or survival between the 147
cases included and those without sufficient material left for the
TMA technique.
Sections (5mm) were dewaxed in xylene, and epitope retrieval
was performed by microwaving for 3 5min in Target Retrieval
Solution pH 6.6 (TRS, Dako, Copenhagen, Denmark) at 500W. The
rabbit polyclonal antibody ID1 (SC-488, Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) was diluted 1:100 and incubated
overnight at 41C. Following microwaving for 3 5min in 0.1 M
Tris-HCl pH 9.0 with 2mM EDTA, sections were incubated with the
rabbit polyclonal antibody ETS-1 (SC-350, Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA, USA) diluted 1:500, for 30min at room
temperature. Immunoperoxidase staining was carried out using
the Dako Envision Kit (Dako, Copenhagen, Denmark) and 3-
amino-9-ethylcarbazole-peroxidase as substrate prior to counter-
staining with Harris haematoxylin. To control for nonspecific
staining, the primary antibodies were preincubated with specific
blocking peptides (SC 488-P and SC 350-P, respectively), and this
procedure completely blocked the staining signal in positive cases.
Also, omission of the primary antibodies was used as a negative
control. The specificity of both antibodies has been reported
(Hollnagel et al, 1999; Nickoloff et al, 2000; Ohtani et al,
2001;Czuwara-Ladykowska et al, 2002; Chambers et al, 2003).
The staining procedures and evaluation of other markers included
have been described previously (Straume et al, 2000; Straume and
Akslen, 2001, 2002), and the results of these are included for
comparison (see Results).
Evaluation of IHC
For all markers, both staining intensity and positive area were
recorded (by one observer). A staining index (values 0–9),
obtained as a product of staining intensity (0–3) and proportion
of immunopositive tumour cells (p10%¼1, 10–50%¼2,
450%¼3), was calculated as previously published (Aas et al,
1996; Straume and Akslen, 1997). For statistical purposes, cutoff
points for continuous variables and staining index categories were
based on the distribution curve for the values.
Statistics
Analyses were performed using the statistical package SPSS ver.
10.1 (Norusis, 1994). Associations between different categorical
variables were assessed by Pearson’s w
2 test. Continuous variables
not following the normal distribution were compared between two
or more groups using the Mann–Whitney U-test or Kruskal–
Wallis H-test. Univariate analyses of time to death due to
malignant melanoma or time to recurrence (recurrence-free
survival) were performed using the product-limit procedure
(Kaplan–Meier method), with date of histologic diagnosis as the
starting point. Patients who died of other causes were censored at
the time of death. Differences between categories were tested by
the log-rank test. The influence of covariates (Breslow’s thickness,
Clark’s level of invasion, anatomic site, ulceration, vascular
invasion, p53 protein expression, p16 protein expression, MVD
and vascular invasion) on patient survival and recurrence-free
survival was analysed by the proportional hazards method (Cox),
including all variables with a P-value p0.15 in univariate analyses,
and tested by the likelihood ratio (lratio) test.
RESULTS
Expression of ID1 protein
ID1 staining was seen in the cytoplasm in positive cases, whereas
nuclear staining was observed only occasionally. Whereas, ID1
expression in stromal cells and keratinocytes was weak or negative,
perivascular cells of intratumoural microvessels were strongly
positive in most cases. Some weak ID1 expression was also
observed in endothelial cells (Figure 1A and B). Normal
melanocytes were negative for ID1 expression.
Only ID1 expression in tumour cells was quantified by the
staining index. In total, 119 cases had sufficient tumour tissue in
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sthe TMA sections to be evaluated for ID1 staining, and only 8 cases
were negative (staining index (SI)p1). In all, 61 cases had a
staining index X4 (median value), and were regarded to have
strong immunohistochemical expression of ID1, whereas 58 cases
had absent/weak expression (SIo4). Increased expression was
significantly associated with increased tumour thickness (Table 1),
and strong expression of ID1 was found significantly more
frequent in primary melanomas located on the trunk, compared
with other sites (w
2 test, P¼0.001). Only a borderline association
was found between ID1 staining and increased proliferation rate by
Ki-67 expression (Table 1). No significant association was present
between ID1 and loss of nuclear p16 protein expression, p16
promoter hypermethylation or p16 mutations. BRAF mutations
have been found in 29% of these melanomas (Akslen et al,i n
press), and strong ID1 expression (SIX4) was significantly higher
among these mutated cases, 71 vs 37% among the others (w
2 test,
P¼0.04). In contrast, NRAS mutations present (in 28% of the
cases (Akslen et al, in press)) were significantly associated with
decreased expression of the ID1-protein (w
2 test, P¼0.034)
(Table 1).
Strong ID1 expression was significantly associated with lower
lymphatic vessel density, whereas no significant correlation was
found with MVD (Table 1). We observed a significant association
between increased ID1 and strong expression of both the tyrosine
kinase receptor EPHA2 as well as its ligand Ephrin-A1 (w
2 test,
P¼0.048 and 0.001, respectively). Increased tumour cell staining
of EPHA2 and Ephrin-A1 was found in 23 and 72%, respectively, in
ID1 strong cases, compared with 9 and 47% in ID1 weak cases.
Thrombospondin-1 expression in the tumour stroma was found in
34% of ID1 strong cases, compared with 57% in ID1 weak cases
(w
2 test, P¼0.014) (Table 1).
Expression of ETS-1 protein
ETS-1 staining was predominantly seen in the cytoplasm of
tumour cells in positive cases, although a mixed nuclear and
cytoplasmic expression pattern was also observed (Figure 1C).
Stromal cells, endothelial cells and perivascular cells, were most
often negative, whereas scattered tumour-infiltrating lymphocytes
were strongly positive in some cases.
A total of 125 cases had sufficient tumour tissue in the TMA
sections to be evaluated for ETS-1 staining in tumour cells; and 26
cases (21%) were regarded to be negative (SIp1). In all, 55 cases
had a staining index X4, and were regarded to have strong
immunohistochemical expression of ETS-1 whereas 70 cases had
weak expression (SIo4). Cases with strong expression of ETS-1
had a significantly lower proliferative rate by Ki-67 (Mann–
Figure 1 (A) Immunohistochemical staining of ID1 protein in human
malignant melanoma. Note the strong cytoplasmic expression in tumour
cells (arrow). Scale bar 50mm. (B) ID1 is strongly positive in perivascular
cells (arrow), and some weaker staining is observed in the endothelial cells
(arrowhead). (C) In this case, ETS-1 protein by immunohistochemistry is
strongly positive in the cytoplasm and nuclei of tumour cells (arrow).
Table 1 Immunohistochemical expression of ID1 in 119 vertical growth
phase (nodular) melanomas in relation to markers of angiogenesis,
lymphangiogenesis and tumour progression
Variable
Absent/low
ID1
expression
a
(n¼58)
High ID1
expression
b
(n¼61) P-value
Median microvessel density
(MVD)
119mm
 2 131mm
 2 0.6
c
Median lymphatic vessel
density (LVD)
12.5mm
 2 2.5mm
 2 0.04
c
Median tumour thickness 3.5mm 4.5mm 0.008
c
Median proliferative rate by
Ki-67
27% 35% 0.08
c
p16 expression present 30 32 NS
p16 expression absent 27 29
BRAF mutations present 4 10 0.044
d
BRAF mutations absent 15 9
NRAS mutations present 11 2 0.034
d
NRAS mutations absent 8 16
Efrin-A1 expression strong 2 16 0.001
d
Efrin-A1 expression weak 53 45
EPHA2 expression strong 5 14 0.048
d
EPHA2 expression weak 49 47
TSP-1 expression strong 32 21 0.014
d
TSP-1 expression weak 24 40
NS¼not significant.
aStaining index o4.
bStaining index X4.
cMann–Whitney U-test.
dPearson’s w
2 test. Bold indicates significant values.
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sWhitney U-test, P¼0.02). Median proliferative rate in cases with
strong expression of ETS-1 was 23%, compared with 31% in cases
with weak expression. There were no associations between ETS-1
staining and expression of p16 or ID1, nor with markers of
angiogenesis or lymphangiogenesis.
Survival analysis
As illustrated by the Kaplan–Meier plot in Figure 2, cases with
increased expression of ID1 protein had significantly decreased
patient survival in univariate survival analysis (log-rank,
P¼0.006). Also, recurrence-free survival was shorter in these
cases (log-rank, P¼0.04). Still, when adjusted for other strong
prognostic factors in this patient series, like tumour thickness and
others, ID1 expression had no independent prognostic significance
in multivariate Cox analysis.
DISCUSSION
In sporadic melanomas, various genetic alterations of p16 have
been reported, such as point mutations (0–26%), promoter
methylation (0–19%), and homozygous deletions (6–25%)(Rocco
and Sidransky, 2001; Straume et al, 2002). Still, no known genetic
or epigenetic event can presently explain the lack of p16 expression
in 45% of melanoma cases that we previously reported (Straume
et al, 2000). Regulation of p16 expression has been suggested for
the ID1 protein, both directly by inhibiting transcriptional
activation at E-boxes within the p16 promoter (Alani et al,
2001), or indirectly through ETS inhibition (Yates et al, 1999;
Ohtani et al, 2001). In melanoma, a recent study suggested a role of
ID1 in regulating p16 expression in some early tumours (Polsky
et al, 2001). In our present study of more advanced primary
tumours, there was no significant association between ID1 or ETS-
1 expression and p16 status, indicating that these regulatory
pathways might not be central for p16 inactivation in these
particular tumours, and other mechanisms are likely to be
involved at different stages of melanoma progression (Hara et al,
1996) (Bartek-Cancer res-96).
Still, strong ID1 expression indicated a more aggressive
melanoma phenotype, and was found to be associated with
increased tumour thickness, primary tumours located on the
trunk, and a tendency towards increased tumour cell proliferation
by Ki-67 expression. In addition, ID1 expression was significantly
related to decreased recurrence-free and patient survival, and this
has previously not been reported. The findings are in accordance
with a few prognostic studies on other tumours. A study of breast
cancer suggested that ID1 can control the malignant progression of
breast cancer cells, particularly when mediated by sex steroid
hormones (Lin et al, 2000). Another breast cancer study found a
negative prognostic impact of increased ID1 expression (Schopp-
mann et al, 2003). Similar results have been published regarding
pancreatic cancer (Lee et al, 2004), cervical cancer (Schindl et al,
2001), and ovarian carcinomas (Schindl et al, 2003). In these
studies, stronger ID1 expression was consistently associated with
poorly differentiated tumours and a more aggressive behaviour.
Loss of ETS-1 expression was significantly associated with
increased tumour cell proliferation by Ki-67 expression, and this is
consistent with a proposed role in cell cycle regulation, although
probably not through the p16 pathway in melanomas. ETS-1 is a
known downstream target of the RAS–RAF–MEK pathway
regulating multiple cellular processes including proliferation
(Graves and Petersen, 1998). Furthermore, a recent study has
suggested that also ID1 expression and RAF/MEK activation might
be related (Cheung et al, 2004). Ling et al (2002) suggested that
proliferation in prostate cancer cells induced through activation of
the Raf/Mek pathway might involve ID1. Notably, we found that
ID1 expression was significantly increased in cases with BRAF
mutations, indicating that ID1 could be a possible downstream
target of this signalling pathway. The balance between ETS-1 or -2
and ID1 has been shown to influence cellular senescence through
p16 protein expression, and this balance is also influenced by the
RAS–RAF–MEK kinase cascade activity (Ohtani et al, 2001). The
possible existence of a functional association between mutated
BRAF and ID1 expression should be further investigated.
Similarly, a significant association between the RTK ligand and
receptor pair ephrin-A1/EPHA2 and ID1 expression was suggested
by our finding of a positive correlation with levels of ID1 protein.
This association has previously not been reported. EPHA2 is
involved in several signalling pathways and is reported to be
overexpressed in many cancers, including melanoma (Nakamoto
and Bergemann, 2002; Straume and Akslen, 2002).
ID1 has been implicated in the regulation of angiogenesis, and
ID1/ID3-deficient mice revealed significant defects in vascularisa-
tion and extensive necrosis (Lyden et al, 2001). In this model,
invasion of endothelial cells into nonvascular tissue, an important
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Figure 2 Survival curves according to the Kaplan–Meier method by ID1
expression in nodular melanomas. (A) Patient survival with death due to
melanoma as end point. (B) Recurrence-free survival by ID1 expression.
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sstep in efficient tumour angiogenesis, was found to be inhibited,
supporting a role of Id proteins as proangiogenic regulators. In a
recent study of pancreatic cancer, increased ID1 expression was
associated with increased MVD (Schoppmann et al, 2003). In an
experimental study, thrombospondin-1 was transcriptionally
repressed by ID1, and ID1 knockout mice showed suppressed
angiogenesis and upregulated levels of TSP-1 (Volpert et al, 2002).
In accordance with this, our results confirm the inverse relation
between ID1 expression and TSP-1, although no significant
association was found with MVD in these human melanomas.
In conclusion, our study suggests a significant role of ID1
protein in melanoma progression and survival. Increased ID1
expression was found in thicker tumours and was significantly
associated with poor prognosis. No significant correlation was
found with p16 alterations or MVD, suggesting that other
regulatory pathways might be influenced by ID1 in these particular
tumours. An inverse relation between ID1 and TSP-1 expression
supports a significant role of ID1 in the regulation of this complex
multitarget protein.
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